Effects of zinc-L-carnosine and vitamin E on aspirin-induced gastroduodenal injury in dogs

J Vet Intern Med. 2011 Jan-Feb;25(1):39-46. doi: 10.1111/j.1939-1676.2010.0638.x. Epub 2010 Nov 23.

Abstract

Background: Nonsteroidal anti-inflammatory drugs frequently cause gastrointestinal (GI) injury. Zinc-L-carnosine has antioxidant, anti-inflammatory, mucosal protective, and healing properties in rodent models and in some human studies of GI injury.

Hypothesis: The combination of zinc-L-carnosine and vitamin E attenuates aspirin-induced gastroduodenal mucosal injury.

Animals: Eighteen healthy random-source Foxhound dogs.

Methods: In this randomized, double-blinded, placebo-controlled study dogs were treated with placebo (n = 6; 0X group), 30 mg/30 IU (n = 6; 1X group), or 60 mg/60 IU (n = 6; 2X group) zinc-L-carnosine/vitamin E orally every 12 hours for 35 days. Between Day 7 and 35, GI mucosal lesions were induced with aspirin (25 mg/kg p.o. q8h). Mucosal injury lesions (hemorrhage, erosion, and ulcer) were assessed by gastroduodenoscopy on Days 14, 21, and 35 with a 12-point scoring scale.

Results: At baseline (Day -1) gastroscopy scores were not significantly different between groups (mean ± SD: 0X, 4.4 ± 0.8; group 1X, 4.4 ± 0.6; group 2X, 4.2 ± 0.3; P= .55). Gastroscopy scores increased significantly in all groups between Day -1 and Days 14, 21, and 35 (P < .0001). On Day 35, gastroscopy scores were 29.2 ± 5.2 (0X), 27.3 ± 3.7 (1X), and 28.6 ± 3.3 (2X). Mean gastroscopy scores were not significantly different among treatment groups on any of the days (P = .61).

Conclusions and clinical importance: Administration of the combination of zinc-L-carnosine and vitamin E at 1X or 2X dosing did not attenuate aspirin-induced gastroduodenal mucosal injury.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Anti-Ulcer Agents / therapeutic use*
  • Aspirin / adverse effects*
  • Aspirin / therapeutic use
  • Body Weight / drug effects
  • Body Weight / physiology
  • Carnosine / analogs & derivatives*
  • Carnosine / therapeutic use
  • Dog Diseases / chemically induced
  • Dog Diseases / drug therapy*
  • Dogs
  • Double-Blind Method
  • Duodenoscopy / veterinary
  • Eating / drug effects
  • Eating / physiology
  • Female
  • Gastric Mucosa / drug effects
  • Gastrointestinal Diseases / chemically induced
  • Gastrointestinal Diseases / drug therapy*
  • Male
  • Organometallic Compounds / therapeutic use*
  • Pilot Projects
  • Statistics, Nonparametric
  • Tocopherols / therapeutic use*
  • Zinc Compounds / therapeutic use

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Anti-Ulcer Agents
  • Organometallic Compounds
  • Zinc Compounds
  • polaprezinc
  • Carnosine
  • Tocopherols
  • Aspirin